Page last updated: 2024-09-03

dibutyryl cyclic-3',5'-cytidine monophosphate and Lymphoma

dibutyryl cyclic-3',5'-cytidine monophosphate has been researched along with Lymphoma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dove, S; Golombek, M; Schwede, F; Seifert, R; Wolter, S1

Other Studies

1 other study(ies) available for dibutyryl cyclic-3',5'-cytidine monophosphate and Lymphoma

ArticleYear
N4-monobutyryl-cCMP activates PKA RIα and PKA RIIα more potently and with higher efficacy than PKG Iα in vitro but not in vivo.
    Naunyn-Schmiedeberg's archives of pharmacology, 2014, Volume: 387, Issue:12

    Topics: Animals; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit; Cyclic AMP-Dependent Protein Kinases; Cyclic CMP; Cyclic GMP-Dependent Protein Kinase Type I; Hydrophobic and Hydrophilic Interactions; Lymphoma; Mice; Models, Molecular; Phosphorylation

2014